#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS
proLékaře.cz / Journals / Clinical Osteology / 2019 - 2

Cushing’s syndrome, glucocorticoids and bone

Czech version

Authors: Kršek Michal
Authors‘ workplace: II. interní klinika 3. LF UK a FN Královské Vinohrady, Praha
Published in: Clinical Osteology 2019; 24(2): 57-61
Category:

Overview

Cushing’s syndrome, both endogenous and exogenous (iatrogenic), is associated with a decrease of bone mass called as glucocorticoid-induced osteoporosis. Among factors playing role in its pathogenesis are: inhibition of bone formation and stimulation of osteoresorption, disturbed bone remodelation, disturbed calcium-phosphate metabolism with negative calcium balance and also disturbed vitamin D metabolism. Prevention of glucocorticoid-induced osteoporosis consists of identification of subjects at increased risk of fractures and introducing measures leading to its decrease. Therapy includes non-pharmacological measures and sufficient intake of calcium and vitamin D. As the first line in medical treatment are recommended bisphosphonates or teriparatide, after discontinuation of teriparatide bisphosphonates or denosumab.

Keywords:

osteoporosis – Cushing’s syndrome – glucocorticoids – treatment

Sources
  1. Cushing HW. The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bull Johns Hopkins Hosp 1932; 50: 137–195.
  2. Ross EJ, Linch DC. Cushing’s syndrome-Killing disease: Discriminatory value of signs and symptoms aiding early diagnosis. Lancet 1982; 2(8299): 646–649. Dostupné z DOI: <http://dx.doi.org/10.1016/s0140–6736(82)92749–0>.
  3. Faggiano A, Pivonello R, Spiezia S et al. Cardiovascular risk factors and common carotid artery calibre and stiffness in patients with Cushing’s disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab 2003; 88(6): 2527–2533. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2002–021558>.
  4. Pivonello R, Faggiano A, Lombardi G et al. The metabolic syndrome and cardiovascular risk in Cushing’s syndrome. Endocrinol Metab Clin North Am 2005; 34(2): 327–339. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ecl.2005.01.010>.
  5. Newell-Price J. Diagnosis/differential diagnosis of Cushing‘s syndrome: a review of best practice. Best Pract Res Clin Endocrinol Metab 2009; 23(Suppl 1): S5-S14. Dostupné z DOI: <http://dx.doi.org/10.1016/S1521–690X(09)70003-X>.
  6. Kršek M, Čáp J, Hána V et al. Doporučení České endokrinologické společnosti pro léčbu Cushingova syndromu v dospělosti. DMEV 2013; 16(1): 63–71.
  7. Nishimura J, Ikuyama S. Glucocorticoid-induced osteoporosis: pathogenesis and management. J Bone Miner Metab 2000; 18(6): 350–352.
  8. Weinstein RS, Jilka RL, Parfitt AM et al. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 1998; 102(2): 274–282. Dostupné z DOI: <http://dx.doi.org/10.1172/JCI2799>.
  9. Weinstein RS. Glucocorticoid-induced osteoporosis. Rev Endocr Metab Disord 2001; 2(1): 65–73.
  10. Robling AG, Niziolek PJ, Baldridge LA et al. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem 2008; 283(9): 5866–5875. Dostupné z DOI: <http://dx.doi.org/10.1074/jbc.M705092200>.
  11. 11.Sivagurunathan S, Muir MM, Brennan TC et al. Influence of glucocorticoids on Human Osteoclast Generation and Activity. J Bone Miner Res 2005; 20(3): 390–398. Dostupné z DOI: <http://dx.doi.org/10.1359/JBMR.041233>.
  12. Jia D, O’Brien CA, Stewart SA et al. Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology 2006; 147(12): 5592–5599. Dostupné z DOI: <http://dx.doi.org/10.1210/en.2006–0459>.
  13. Kim HJ, Zhao H, Kitaura H et al. Glucocorticoids suppress bone formation via the osteoclast. J Clin Invest 2006; 116(8): 2152–2160. Dostupné z DOI: <http://dx.doi.org/10.1172/JCI28084>.
  14. Swanson C, Lorentzon M, Conaway HH et al. Glucocorticoid regulation of osteoclast differentiation and expression of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand, osteoprotegerin, and receptor activator of NF-kappaB in mouse calvarial bones. Endocrinology 2006; 147(7): 3613–3622. Dostupné z DOI: <http://dx.doi.org/10.1210/en.2005–0717>.
  15. Canalis E, Mazziotti G, Giustina A et al. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporosis Int 2007; 18(10): 1319–1328. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–007–0394–0>.
  16. van Staa TP, Leufkens HG, Cooper C. The epidemiology corticosteroid-induced osteoporosis: a meta-analysis. Osteoporosis Int 2002; 13(10): 777–787. Dostupné z DOI: <http://dx.doi.org/10.1007/s001980200108>.
  17. Kanis JA, Johansson H, Oden A et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004; 19(6): 893–899. Dostupné z DOI: <http://dx.doi.org/10.1359/JBMR.040134>.
  18. Angeli A, Guglielmi G, Dovio A et al. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone 2006; 39(2): 253–259. Dostupné z DOI: <http://dx.doi.org/10.1016/j.bone.2006.02.005>.
  19. van Staa TP, Leufkens HG, Abenhaim L et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000; 15(6): 993–1000. Dostupné z DOI: <http://dx.doi.org/10.1359/jbmr.2000.15.6.993>.
  20. van Staa TP, Laan RF, Barton IP et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 2003; 48(11): 3224–3229. Dostupné z DOI: <http://dx.doi.org/10.1002/art.11283>.
  21. Vittelius G, Trabado S, Bouligand J et al. Pathophysiology of glucocorticoid signalling. Ann Endocrinol (Paris) 2018; 79(3): 98–106. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ando.2018.03.001>.
  22. Leib ES, Saag KG, Adachi JD et al. Official positions for FRAX® clinical regarding glucocorticoids: the impact of the use of glucocorticoids on the estimate by FRAX® of the 10 year risk of fracture: from Joint official positions development conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®. J Clin Densitometry 2011; 14(3): 212–219. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jocd.2011.05.014>.
  23. van Staa T. Pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcified Tissue Int 2006; 79(3): 129–137. Dostupné z DOI: <http://dx.doi.org/10.1007/s00223–006–0019–1>.
  24. Kim BJ, Kwak MK, Ahn SH et al. The association of cortisol and adrenal androgen with trabecular bone score in patients with adrenal incidentaloma with and without autonomous cortisol secretion. Osteoporos Int 2018; 29(10): 2299–2307. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–018–4608–4>.
  25. Kanis JA, Oden A, Johansson H et al. FRAX and its applications to clinical practice. Bone 2009; 44(5): 734–743. Dostupné z DOI: <http://dx.doi.org/10.1016/j.bone.2009.01.373>.
  26. 26.Kanis JA, Johansson H, Oden A et al. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int 2011; 22(3): 809–816. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–010–1524–7>.
  27. Tatsuno I, Sugiyama T, Suzuki S et al. Age dependence of early symptomatic vertebral fracture with high-dose glucocorticoid treatment for collagen vascular diseases. J Clin Endocrinol Metab 2009; 94(5): 1671–1677. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2008–1578>.
  28. Buckley L, Humphrey MB. Glucocorticoid-induced osteoporosis. N Engl J Med 2019; 379(26): 2547–2556. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMcp1800214>.
  29. Buckley L, Guyatt G, Fink HA et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol 2017; 69(8): 1521–1537. Dostupné z DOI: <http://dx.doi.org/10.1002/art.40137>. Erratum in Error in Optimized Calcium Dosage Shown in Table 2 of the Article by Buckley et al (Arthritis Rheumatol, August 2017). [Arthritis Rheumatol 2017].
  30. Glüer CC, Marin F, Ringe JD et al. Comparative effects of teriparatide and risendronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial. J Bone Miner Res 2013; 28(6): 1355–1368. Dostupné z DOI: <http://dx.doi.org/10.1002/jbmr.1870>.
  31. Saag KG, Wagman RB, Geusens P et al. Denosumab versus risendronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol 2018; 6(6): 445–454. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–8587(18)30075–5>.
  32. Mok CC, Ying KY, To CH et al. Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial. Ann Rheum Dos 2011; 70(5): 778–784. Dostupné z DOI: <http://dx.doi.org/10.1136/ard.2010.143453>.
Labels
Clinical biochemistry Paediatric gynaecology Paediatric radiology Paediatric rheumatology Endocrinology Gynaecology and obstetrics Internal medicine Orthopaedics General practitioner for adults Radiodiagnostics Rehabilitation Rheumatology Traumatology Osteology
Profesor Jaroslav Blahoš a slovenská osteológia
Profesor Jaroslav Blahoš, jak jsem ho znal
Calcitonin: hormone into oblivion
Can affecting of subchondral bone slow the progression of osteoarthritis?
Prevention and treatment of osteoporosis: causal or symptomatic?
Current opinion on premenopausal osteoporosis
Extraskeletal risk factors for fractures in older age
Article was published in

Clinical Osteology

Issue 2
2019 Issue 2
Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#